PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRucaparib
Rubraca(rucaparib)
Rubraca (rucaparib) is a small molecule pharmaceutical. Rucaparib was first approved as Rubraca on 2016-12-19. It is used to treat ovarian neoplasms in the USA. It has been approved in Europe to treat ovarian neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Rubraca
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rucaparib camsylate
Tradename
Company
Number
Date
Products
RUBRACAPharma&N-209115 RX2016-12-19
3 products, RLD, RS
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ovarian neoplasmsEFO_0003893D010051C56
Agency Specific
FDA
EMA
Expiration
Code
RUCAPARIB CAMSYLATE, RUBRACA, ZR PHARMA
2025-04-06ODE-168
2023-12-19ODE-126
2023-05-15I-830
Patent Expiration
Patent
Expires
Flag
FDA Information
Rucaparib Camsylate, Rubraca, Zr Pharma
99872852035-08-17DP
101306362035-08-17U-2012, U-2101, U-2273, U-2830
88595622031-08-04U-2012, U-2273, U-2830
87540722031-02-10DS, DP
90454872031-02-10DS, DP
98616382031-02-10U-2012, U-2273
102789742031-02-10DP
80715792027-08-12U-2012, U-2273, U-2830
81432412027-08-12U-2012, U-2273, U-2830
73517012024-07-23U-2012, U-2273, U-2830
75315302024-07-23U-2012, U-2273, U-2830
64955412023-11-22DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XK: Poly (adp-ribose) polymerase (parp) inhibitors
— L01XK03: Rucaparib
HCPCS
No data
Clinical
Clinical Trials
68 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C801072—319
Ovarian neoplasmsD010051EFO_0003893C56664——13
Fallopian tube neoplasmsD005185——455—113
Peritoneal neoplasmsD010534——233——7
Castration-resistant prostatic neoplasmsD064129——233——7
Prostatic neoplasmsD011471—C61241——6
Ovarian epithelial carcinomaD000077216———23—16
AdenocarcinomaD000230———21——3
Large cell carcinomaD018287————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5033———6
Endometrial neoplasmsD016889EFO_0004230—14———4
Small cell lung carcinomaD055752——13———3
Pancreatic neoplasmsD010190EFO_0003860C2513———3
CarcinosarcomaD002296——11———2
Uterine cervical neoplasmsD002583HP_0030159——2———2
Biliary tract neoplasmsD001661—C24.912———2
Non-small-cell lung carcinomaD002289——12———2
Urologic neoplasmsD014571—C64-C6812———2
Malignant mesotheliomaD000086002———1———1
Show 15 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Female genital neoplasmsD005833——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRucaparib
INNrucaparib
Description
Rucaparib is a member of the class of azepinoindoles that is 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one carrying additional 4-[(methylamino)methyl]phenyl and fluoro substituents at positions 2 and 8 respectively. It is an inhibitor of poly (ADP-ribose) polymerase and is used (as the camsylate salt) as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation. It has a role as an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor and an antineoplastic agent. It is an azepinoindole, a member of caprolactams, an organofluorine compound and a secondary amino compound. It is a conjugate base of a rucaparib(1+).
Classification
Small molecule
Drug classpoly-ADP-ribose polymerase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1
Identifiers
PDB—
CAS-ID283173-50-2
RxCUI—
ChEMBL IDCHEMBL1173055
ChEBI ID—
PubChem CID9931954
DrugBankDB12332
UNII ID8237F3U7EH (ChemIDplus, GSRS)
Target
Agency Approved
PARP1
PARP1
Organism
Homo sapiens
Gene name
PARP1
Gene synonyms
ADPRT, PPOL
NCBI Gene ID
142
Protein name
poly [ADP-ribose] polymerase 1
Protein synonyms
ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase), ADP-ribosyltransferase diphtheria toxin-like 1, ADP-ribosyltransferase NAD(+), ADPRT 1, ARTD1, DNA ADP-ribosyltransferase PARP1, NAD(+) ADP-ribosyltransferase 1, poly (ADP-ribose) polymerase family, member 1, poly(ADP-ribose) synthetase, poly(ADP-ribosyl)transferase, Poly[ADP-ribose] synthase 1, Protein poly-ADP-ribosyltransferase PARP1
Uniprot ID
Q8IUZ9
Mouse ortholog
Parp1 (11545)
poly [ADP-ribose] polymerase 1 (P11103)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,768 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,497 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use